Kimberly Ann Pierwola

• Promotion of Eltrombopag for Immune Thrombocytopenia and Iptacopan for Paroxysmal Nocturnal Hemoglobinuria throughout CT
• Regional Field Trainer 2024
• Current ITP Sales 12th Nationally
• Marketing and Training Liaison and Senior Leadership Consultant supporting Launch Readiness Programs for PNH
• Ultra-rare Disease Sales Consultant Internally
• Highest Reach/Access in NE

• Promotion of Two Oral TKI's, Brigatinib and Mobocertinib, for Specific Driver Mutations in Rare Subsets of Metastatic NSCLC Patients throughout CT, RI, Western MA, and Upstate NY
• Annual Sales Growth of 199%
• Successful Launch of First Targeted Therapy for EXON 20 Mutated NSCLC with HIGH KPIs Including Reach, New Patient Starts at Key Institutions including Yale and RI Hospital
• Strong Access at Key Accounts

• Promotion and Management of New Haven, CT Territory Supporting ADC technology, Enfortumab Vendotin, in the Locally Advanced and Metastatic Urothelial Carcinoma Space
• NE Number One District Nationwide; New Haven Territory 8th Highest Volume Nationwide Q3 2020
• NE District Finished 100% Q4 2020
• New Haven Territory Recognized for Fifth Largest Number of Ordering Accounts Nationwide 2020

• Education, Marketing and Sales of Unique Antibody Portfolio to Hematologists, Oncologists, Nephrologists, Critical Care, ER Hospitalists, and Other Sub Specialists to Identify and Support the Appropriate Management of Rare Hematologic Disorders of the Complement System, PNH and aHUS in CT, NY, and Western MA
• Highly Successful Launch of Second Generation Long-Acting Complement Inhibitor, Ravulizumab, for Paroxysmal Nocturnal Hemoglobinuria; 75% conversion rate first year; lead nation by 15%
• Finished Top 15% of all Regional Account Managers 2019
• Quarter 1 2020; 4th Ranking Nationwide

• Managed Hematology Portfolio Consisting of Three Approved Agents to Community and Academic Physicians Managing Multiple Myeloma, Mantle Cell Lymphoma, Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia Throughout CT and RI
• Successfully Launched First Oral Proteasome Inhibitor for Myeloma, Ixazomib, in 2015 Finishing Top 25% 2016 and 2017
• Grew Territory Sales 49% Representing $5M in Annual Sales 2016-2017
• Quadrupled Annual Bortezomib Sales in Eight Years Representing $16M in Annual Sales
• Highest Volume In Northeast Region for Bortezomib Sales 2010-2017
• Lead Development and Implementation of Nationwide Physician Directed EBLAST Campaigns
• Oral Marketing Launch Committee Member
• Regular and Established Marketing, Training, and Patient Advocacy Board Member

Marketing and Sales of Oncology/Hematology Portfolio to Community and Academic Centers throughout CT and RI

• Grew Amifostine, Novel Radio/Cytoprotective Agent Sales 57% in Four Years Resulting in Sales of $2.5M
• #2 Volume in Northeast FY 2005-2006, FY 2004-2005
• Top % to Goal, 126%, Top Volume in Region 2003-2004
• President's Club FY 2001-2002
• Sales Management Training Completed 2001